Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: Inhalant
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sino Biopharmaceutical
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for TQC-3927](https://pryzm-maps.s3.us-west-2.amazonaws.com/12current_maps.png)
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Chronic Obstructive Pulmonary Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
TQC3927-I-01 | P1 |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease |
2024-12-01 |
53% |